The mixing of drug products during the manufacturing and bottling process may cause medical issues to the unaware consumer, says Alabama liability attorney Keith T. Belt
Novartis Consumer Health, Inc. has announced a voluntarily recall of all lots of select bottle packaging configurations of Excedrin and NoDoz products with expiration dates of Dec. 20, 2014 or earlier, as well as Bufferin and Gas-X Prevention products with expiration dates of Dec. 20, 2013 or earlier. According to an FDA press release, the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets.
The list of affected bottles are:
All lots of Bufferin® products with expiry dates of December 20, 2013 or earlier.
Bufferin® Extra Strength Tablets
Bufferin® Low Dose Tablets
Bufferin® Regular Strength Tablets
All lots of the following Excedrin® products have been recalled with expiry dates of December 20, 2014 or earlier
Excedrin® Extra Strength Caplets
Excedrin® Extra Strength Express Gel Caplets
Excedrin® Extra Strength Gel Caplets
Excedrin® Extra Strength Tablets
Excedrin® Back & Body Caplets
Excedrin® Sinus Headache Caplets
Excedrin® Migraine Caplets
Excedrin® Migraine Gel Tablets
Excedrin® Migraine Tablets
Excedrin® Menstrual Complete Express Gel Caplets
Excedrin® PM Caplets
Excedrin® PM Express Gel Caplets
Excedrin® PM Tablets
Excedrin® Tension Headache Caplets
Excedrin® Tension Headache Express Gel Caplets
Excedrin® Tension Headache Gel Tablets
All lots of Gas-X® Prevention® products with expiry dates of December 20, 2013 or earlier.
All lots of NoDoz® products with expiry dates of December 20, 2014 or earlier
According to the FDA release, “mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient. This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient.”
The release goes on to say consumers that have the product(s) being recalled should stop using the product(s) and contact the Novartis Consumer Relationship Center at 1-888-477-2403 (available Monday-Friday 8 a.m. to 7 p.m. Central Time) for information on how to return the affected products and receive a full refund. For more detailed information, consumers should visit the Norvartis website at http://www.novartis-otc.com/otc/index.html Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.